ClinicalTrials.gg
RecruitingNCT04664517Updated Nov 17, 2026

Casting Versus Flexible Intramedullary Nailing in Displaced Pediatric Forearm Shaft Fractures

An interventional study of Flexible intramedullary nail (FIN) and Reduction auder general anesthesia and long arm cast in Both Bone Forearm Fracture, AO Classification 22D/2.1-5.2 and 7-12 Year Old, sponsored by Helsinki University Central Hospital. Recruiting at 6 sites in 2 countries. Open to participants aged 7 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Helsinki University Central Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2021; still recruiting 5 years 6 months later.
Updated Nov 17, 2026First site in EstoniaPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
7 Years to 12 Years
Sex
All
01

Study summary

The forearm is the most common fracture location in children, with an increasing incidence. Displaced forearm shaft fractures have traditionally been treated with closed reduction and cast immobilization. Diaphyseal fractures in children have poor remodeling capacity, and malunion can thus cause permanent cosmetic and functional disability. Internal fixation especially with flexible intramedullary nails has gained increasing popularity, without evidence of a better outcome compared to closed reduction and cast immobilization.

Read the detailed description

This is a multicenter, randomized superiority trial comparing closed reduction and cast immobilization to flexible intramedullary nails in 7-12 year old children with > 10° of angulation and/or > 10mm of shortening in displaced both bone forearm shaft fractures (AO-pediatric classification: 22D/2.1-5.2). A total of 78 patients with minimum 2 years of expected growth left are randomized in 1:1 ratio to either treatment group. The study has a parallel non-randomized patient preference arm. Both treatments are performed under general anesthesia. In the cast group a long arm cast is applied for 6 weeks. The flexible intramedullary nail group is immobilized in a collar and cuff sling for 4 weeks. Data is collected at baseline and at each follow-up until 1 year.

Primary outcome is 1) PROMIS Pediatric Item Bank v2.0 - Upper Extremity and 2) forearm pronation-supination range of motion at one-year follow-up. Secondary outcomes are Quick DASH, Pediatric pain questionnaire, Cosmetic VAS, wrist range of motion as well as any complications (malunion, delayed union, non-union or deep wound infection, peripheral nerve injury, need for re-intervention during 1-year follow-up) and costs of treatment.

The investigators hypothesize that flexible intramedullary nailing results in a superior outcome.

02

Conditions studied

  • Both Bone Forearm Fracture
  • AO Classification 22D/2.1-5.2
  • 7-12 Year Old
03

In context

Lead sponsor

Helsinki University Central Hospital is the lead sponsor of 311 studies on the registry; 61 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
7 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 7 to12 year old children
  • Open distal radial physis
  • Both bone forearm shaft fractures (AO-pediatric classification: 22D/2.1-5.2)
  • More than 10 degrees of angulation
  • with or without less than 10mm of shortening

Exclusion criteria

Exclusion Criteria:

  • Patients with bilateral fractures
  • Gustilo-Anderson grade I-III open fracture
  • Neurovascular deficit
  • Compartment syndrome
  • Pathologic fracture
  • Patient not able to give a written
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Active comparator
    FIN (Flexible intramedullary nail)

    Fracture reduction and fixation using flexible intramedullary nails. Nails size is 0.4 times the smallest diameter of the medullary canal of radius or ulna measured in radiographs.

    Procedure: Flexible intramedullary nail (FIN)

  • Active comparator
    Long arm cast

    Fractures are reduced under general anesthesia within 3 days from injury and a synthetic circular above elbow cast in neutral pro-supination is applied for six weeks.

    Procedure: Reduction auder general anesthesia and long arm cast

  • Other
    Patient Choice FIN

    Fracture reduction and fixation using flexible intramedullary nails. Nails size is 0.4 times the smallest diameter of the medullary canal of radius or ulna measured in radiographs.

    Procedure: Flexible intramedullary nail (FIN)

  • Other
    Patient Choice cast

    Fractures are reduced under general anesthesia within 3 days from injury and a synthetic circular above elbow cast in neutral pro-supination is applied for six weeks.

    Procedure: Reduction auder general anesthesia and long arm cast

Interventions

  • ProcedureFlexible intramedullary nail (FIN)

    Both bone FIN

  • ProcedureReduction auder general anesthesia and long arm cast

    Reduction and cast

06

What researchers measure

Primary outcomes

  1. PROMIS Pediatric Item Bank v2.0 - Upper Extremity

    We aim to confirm that 75 percent of FIN patients have a better PROMIS UE score than what the mean score of the cast patients will be assuming both groups have the same standard deviation. PROMIS (Patient-Reported Outcomes Measurement Information System) scores are normalized to a mean score of 50, standard deviation of 10, with a theoretical range of 0 to 100. A higher score corresponds to a greater amount of the domain being measured.

    Time frame: 12 months

  2. Pro-supination

    Difference (percent) in forearm pronation-supination range of motion (ROM) at one-year follow-up in comparison to uninjured side.

    Time frame: 12 months

Secondary outcomes

  1. Quick Disabilities of the Arm, Shoulder and Hand score

    Minimum value is 0 and maximum 100. Higher value indicates worse function. Statistically significant difference in QuickDASH score is 6.8 (18) at 12 months FU.

    Time frame: 6 weeks, 3, 6 and 12 months

  2. Measurement Model for the Pediatric Quality of Life Inventory (PedsQL)

    Minimum value is 0 and maximum value is 100. Higher score indicates better health related quality of life.

    Time frame: 6 weeks, 3, 6 and 12 months

  3. Measurement Model for the Pediatric Quality of Life Inventory Pediatric Pain Questionaire (PEDS QL PPQ)

    Minimum value 0 maximum value 10. Higher value indicates higher pain intensity

    Time frame: 6 weeks, 3, 6 and 12 months

  4. Need for re-interventions

    Minimum value 0 no maximum value. Lower value indicates better outcome.

    Time frame: 6 weeks, 3, 6 and 12 months

  5. Rate of participants with malunion

    malunion, delayed union (defined as nonunion at 3 months or later), pseudoarthrosis (defined as 3 cortices out of 4 not united at 6 months or later)

    Time frame: 6 weeks, 3, 6 and 12 months

  6. Adverse effects

    adverse effects (wound infection, nerve or/and tendon damage)

    Time frame: 6 weeks, 3, 6 and 12 months

  7. Cosmetic VAS

    Minimum value 0 maximum value 10. Higher value indicates better satisfaction

    Time frame: 6 weeks, 3, 6 and 12 months

  8. PROMIS Pediatric Item Bank v2.0 - Upper Extremity

    Difference between treatment groups

    Time frame: 6 weeks, 3, 6 months

  9. Upper limb ROM

    Difference (percent) in elbow, wrist flexion extension and pronation-supination in comparison to uninjured side

    Time frame: 6 weeks, 3, 6 months

  10. Return to sport/musical instrument and level

    Level of practiced sport or musical instrument before and at end of trial, as well as time from injury to return to hobby is registered.

    Time frame: 6 weeks, 3, 6 and 12 months

07

Study locations

3 of 6 sites recruiting
08

References and documents

Publications

  • Grahn P, Sinikumpu JJ, Nietosvaara Y, Syvanen J, Salonen A, Ahonen M, Helenius I. Casting versus flexible intramedullary nailing in displaced forearm shaft fractures in children aged 7-12 years: a study protocol for a randomised controlled trial. BMJ Open. 2021 Aug 20;11(8):e048248. doi: 10.1136/bmjopen-2020-048248. PubMed 34417215 ↗

Individual participant data

Plan to share: Yes — All data will be available upon request. Data will be delivered as anonymized.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Study protocol is published in BMJ open. What can not be found there can be shared by contacting the main investigator.

Access criteria: Please see the study protocol in BMJ open

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2021 (actual). Primary completion is estimated for Dec 2027, 79 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Dec 2024 → Dec 2027 and completion Dec 2024 → Dec 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2020
First posted
Dec 11, 2020
StartActual
May 1, 2021
Primary completionEst.
Dec 31, 2027was Dec 2024
CompletionEst.
Dec 31, 2030was Dec 2024
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added — first site in Estonia
Show site
  • Tallinna Lastehaigla · Tallinn, Estonia
Nov 17, 2026
Primary completion
Dec 31, 2024→Dec 31, 2027
Nov 17, 2026
Study completion
Dec 31, 2024→Dec 31, 2030
Nov 17, 2026
Enrollment
90→160
Nov 17, 2026
Eligibility
Revised
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    1 site added — first site in Estonia
    Show site
    • Tallinna Lastehaigla · Tallinn, Estonia
    Primary completion Dec 31, 2024→Dec 31, 2027
    Study completion Dec 31, 2024→Dec 31, 2030
    Enrollment 90→160
    Eligibility Revised
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04664517
Responsible party
Petra Grahn (Hand Surgeon, Principal investigator, Helsinki University Central Hospital) — Principal investigator
First posted
Dec 11, 2020
Start date
May 1, 2021
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Nov 17, 2026

Study contacts

Petra Grahn, MD
Contact
petra.grahn@hus.fi
+35894711
Ilkka Helenius, MD
study director · Helsinki University Central Hospital
Petra Grahn, MD
principal investigator · Helsinki University Central Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion